The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 560.00
Bid: 550.00
Ask: 566.00
Change: 0.00 (0.00%)
Spread: 16.00 (2.909%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 560.00
GHH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Year Trading Update

7 Apr 2021 07:00

RNS Number : 5818U
Gooch & Housego PLC
07 April 2021
 

For immediate release

7 April 2021

 

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Half Year Trading Update

 

"Recovery of industrial laser demand and further progress streamlining manufacturing"

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update on trading in the six months ended 31 March 2021.

Trading

In the first half of the financial year we have seen a recovery in the industrial laser sector in line with the trends previously announced in our AGM trading statement in February 2021. Demand for fibre optics, hi- reliability fibre couplers and our life sciences products and services remains strong. Our Defence markets have been robust, whilst demand from our limited number of commercial aerospace customers has been affected by current end-market conditions.

 

The Asian markets have led the recovery in industrial lasers and we are now seeing the US and European markets also emerging from the pandemic downturn. The roll out of new technologies such as 5G, along with greater use of new materials in microelectronic manufacturing has fuelled demand, building on the sustained growth in semiconductors.

 

In the UK we have secured important new A&D business for our UK Precision Optic (PO) hub, adding to the strong US Defence order book.

 

Medical diagnostics has continued to demonstrate good growth and we are now seeing improving levels of demand for our specialist medical laser products, which were adversely affected by the reduction in elective procedures in FY 2020 owing to COVID-19.

 

As at 31 March 2021 our order book was at £92.8 million (31 March 2020: £91.7 million), an increase of 1.3%, or 7.9% at constant currency, compared with the same time last year.

 

Operations

 

We are proud of the way our staff have responded to the challenge of the pandemic. All of our sites remain fully open and are operating in line with all relevant health and safety rules and regulations. Nevertheless, travel restrictions and some staff self isolating have presented hurdles that we have worked hard to overcome. We anticipate that these issues will ease as the vaccine roll out progresses in the UK and USA.

 

As part of the Company's ongoing performance improvement programme we are making good progress streamlining our manufacturing sites. As previously reported all of the product lines at our Glenrothes, Scotland facility have been transferred to our new UK PO hub in Ilminster and the Glenrothes site has been closed. Outsourcing of the Acousto Optic (AO) products from Ilminster to our contract manufacturer in Asia is progressing well and we expect this to be substantially complete by the end of the current financial year. The costs and full year benefits of the above mentioned moves are expected to be in line with previous communications.

 

Our two further site streamlining projects are also progressing to plan. Production at our Baltimore, MD facility is in the process of being transferred to our Boston, MA and Torquay, Devon facilities and our Baltimore site will be closed. We are also transferring production from our facility in St Asaph, Wales to our UK PO hub in Ilminster. We will retain an optical systems engineering and design centre in St Asaph, housing our world leading optical systems engineers.

 

We are on track to complete both projects by the end of the current financial year and to reap the full year benefits of the reduced cost base in FY2022.

 

Financial Strength

 

The Group's cash generation in the first half of the financial year has been strong. The payment of the final earn out associated with the acquisition of the ITL business has been completed, with that business achieving at its maximum target level. In the first half of the year the Group's liquidity levels improved and total headroom from existing facilities has increased.

 

Continued execution of our strategy

 

Our long standing strategic objectives are to diversify our business and move up the value chain. We continue to make considerable progress against these objectives and we are securing important new orders thanks to our growing systems capability across all three of our business sectors.

 

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"Trading in the first half of the financial year has been in line with our expectations. A broader based recovery of the industrial laser market is encouraging, driven by new technologies such as 5G and stronger, more flexible materials used in smart phone and tablet screens.

"We are very proud of the way our staff have responded to the challenge of the pandemic. The vaccine roll out programme in the UK and USA should enable some of the restrictions and hurdles associated with the pandemic to ease however, our priority remains the health and safety of all our staff, customers and suppliers.

"G&H has made significant progress with the streamlining of our manufacturing base. We are on track to have substantially completed all of the ongoing projects by the end of the financial year. This will enable us to reap the full year effects in FY2022.

"The challenge of the pandemic has validated our long term strategic goals of diversification and moving up the value chain. We intend to vigorously pursue these goals through internal investment and where appropriate, acquisitions."

 

The Company's Interim Results, for the six months ended 31 March 2021, are expected to be announced on Tuesday 1 June 2021.

 

 

For further information contact: -

 

 

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Sophie Wills/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

 

 

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA, Europe and China. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFFDSAIRIIL
Date   Source Headline
4th Apr 20247:00 amRNSHalf Year Trading Update
18th Mar 20242:36 pmRNSDivestment of EM4
29th Feb 20247:00 amRNSDirector/PDMR Shareholding
27th Feb 20243:26 pmRNSNotification of Major Holdings
22nd Feb 20244:07 pmRNSNotification of Major Holdings
21st Feb 202412:31 pmRNSResult of AGM
21st Feb 202410:28 amRNSDirector/PDMR Shareholding
21st Feb 20249:43 amRNSDirector/PDMR Shareholding
21st Feb 20247:00 amRNSAGM Trading Update
12th Jan 20247:00 amRNSAnnual Report and Notice of AGM
10th Jan 20247:00 amRNSGrant of LTIP Awards
9th Jan 202411:53 amRNSNotification of Major Holdings
8th Jan 20243:57 pmRNSNotification of Major Holdings
4th Jan 20243:20 pmRNSDirector/PDMR Shareholding
5th Dec 20237:00 amRNSResults for the year ended 30 September 2023
8th Nov 20237:00 amRNSNotification of Full Year Results
23rd Oct 20232:23 pmRNSHolding(s) in Company
3rd Oct 20237:00 amRNSFull Year Trading Update
2nd Oct 20232:44 pmRNSHolding(s) in Company
9th Aug 20236:15 pmRNSDirector/PDMR Shareholding
31st Jul 20238:22 amRNSHolding(s) in Company
21st Jul 202311:58 amRNSCompletion of Acquisition and Issue of Equity
19th Jul 20237:00 amRNSAcquisition of Artemis Optical
23rd Jun 20234:11 pmRNSHolding(s) in Company
21st Jun 202310:26 amRNSDirector/PDMR Shareholding
20th Jun 20236:00 pmRNSAcquisition of GS Optics
6th Jun 20237:00 amRNSInterim Results
23rd May 20237:00 amRNSNotification of Half Year Results
3rd May 20238:56 amRNSIssue of Equity
4th Apr 20237:00 amRNSHalf Year Trading Update
30th Mar 20239:33 amRNSHolding(s) in Company
15th Mar 202312:00 pmRNSAppointment of Non-Executive Director
3rd Mar 20234:37 pmRNSHolding(s) in Company
2nd Mar 20231:10 pmRNSHolding(s) in Company
1st Mar 20239:44 amRNSHolding(s) in Company
22nd Feb 20231:50 pmRNSResult of AGM
22nd Feb 20237:00 amRNSAGM Trading Update
8th Feb 202312:59 pmRNSHolding(s) in Company
9th Jan 202311:44 amRNSGrant of LTIP Awards
21st Dec 202210:02 amRNSPosting of Annual Report and Notice of AGM
20th Dec 202212:30 pmRNSDirector/PDMR Shareholding
6th Dec 20224:26 pmRNSDirector/PDMR Shareholding
6th Dec 20229:38 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSResults for the year ended 30 September 2022
25th Nov 20223:17 pmRNSHolding(s) in Company
23rd Nov 20224:27 pmRNSHolding(s) in Company
18th Nov 20222:20 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSNotification of Full Year Results
27th Oct 202212:56 pmRNSHolding(s) in Company
18th Oct 20222:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.